Source comparison
CJC-1295 DAC vs Modified GRF(1-29) — Why the Distinction Matters
The peptide community often uses 'CJC-1295' to refer to two structurally different compounds. CJC-1295 with DAC (the albumin-binding version) has a half-life of 6–8 days and is dosed 1–2 times weekly at 30–60 mcg/kg. Modified GRF(1-29), also called CJC-1295 no
This comparison does not assign a generated winner or score.
- The peptide community often uses 'CJC-1295' to refer to two structurally different compounds. CJC-1295 with DAC (the albumin-binding version) has a half-life of 6–8 days and is dosed 1–2 times weekly at 30–60 mcg/kg. Modified GRF(1-29), also called CJC-1295 no DAC or Mod GRF, lacks the lysine modification and has a half-life of approximately 30 minutes. It requires dosing 1–3 times daily, typically in 100 mcg pulses, and is almost always combined with a GHRP (growth hormone-releasing peptide) like ipamorelin or GHRP-2 to amplify the GH spike.
- Using CJC-1295 for anti-aging research evidence requires clarity on which version you're referencing. The clinical trials with sustained IGF-1 elevation used the DAC version exclusively. The non-DAC analogue mimics physiological GH pulsatility more closely but demands frequent administration and produces transient rather than sustained IGF-1 changes. For longevity protocols focused on maintaining baseline elevation rather than peak spikes, the DAC version is the supported choice.
- We've seen research groups dose modified GRF weekly based on CJC-1295 DAC literature. The result is negligible IGF-1 response because the peptide clears within hours. Conversely, dosing true CJC-1295 DAC daily creates supraphysiological IGF-1 levels (300+ ng/mL sustained) that increase risk of insulin resistance and acromegaly-like side effects. The compound names are used interchangeably in supplier catalogs, but the pharmacology is not interchangeable.